Research ArticleOriginal Article

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma

Ruichao Chai, Guanzhang Li, Yuqing Liu, Kenan Zhang, Zheng Zhao, Fan Wu, Yuzhou Chang, Bo Pang, Jingjun Li, Yangfang Li, Tao Jiang and Yongzhi Wang
Cancer Biology & Medicine February 2021, 18 (1) 271-282; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0179

Article Information

vol. 18 no. 1 271-282
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2020.0179
Published By 
Cancer Biology & Medicine
History 
  • Received April 17, 2020
  • Accepted August 11, 2020
  • Published online February 1, 2021.
Copyright & Usage 
Copyright: © 2021, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Ruichao Chai1,*,
  2. Guanzhang Li1,*,
  3. Yuqing Liu1,
  4. Kenan Zhang1,
  5. Zheng Zhao1,
  6. Fan Wu1,
  7. Yuzhou Chang2,
  8. Bo Pang1,
  9. Jingjun Li1,
  10. Yangfang Li1,
  11. Tao Jiang1,2⇑ and
  12. Yongzhi Wang1,2⇑
  1. 1Department of Molecular Neuropathology, Beijing Neurosurgical Institute; Chinese Glioma Genome Atlas Network (CGGA), Capital Medical University, Beijing 100070, China
  2. 2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
  1. Correspondence to: Tao Jiang and Yongzhi Wang, E-mail: Taojiang_1964{at}163.com and yongzhiwang_bni{at}163.com
View Full Text

Cited By...

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Subjects

Keywords